ClinicalTrials.gg
RecruitingNCT06840496Updated Mar 27, 2026

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

A Phase 3 interventional study of Bionetide and Placebo in Rett Syndrome, sponsored by Biomed Industries, Inc.. Recruiting at 18 sites in 2 countries. Open to female participants aged 5 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Biomed Industries, Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
5 Years to 20 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Rett Syndrome with a site in United States — 11 open to participants now, 21 under way, 5 of them phase 3. Rett Syndrome · United States.

Planned enrollment
Largest of 34
210 · median 32
Started
2026
with 3 others
Phase 3
11 of 55
2 open now
Primary completion
2027-09
later than 11 of 20 live
Registered
49th of 55
by date
Lead sponsor
2 of 55
Biomed Industries, Inc.

Among the 55 studies in Rett Syndrome with a site in United States, this one has the largest planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 11 of the 20 other live ones, and was the 49th registered.

Rett Syndrome

96 studies on the registry are indexed under Rett Syndrome; 19 are open to participants now.

Browse Rett Syndrome studies →

Open to participants now

11 of the 55 studies in Rett Syndrome with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Rett Syndrome studies recruiting now, 4 (29%) set no upper age limit and 7 (50%) stop at 75 or younger; 12 take children under 18; 3 take healthy volunteers.

This study: 5 Years to 20 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Rett Syndrome with a site in United States, or all of them as a file.
02

Study summary

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome

Key Secondary Objective

  • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Read the detailed description

Co-Primary Endpoints

  • Rett Syndrome Behavior Questionnaire (RSBQ) total score - Change from Baseline to Week 12
  • Clinical Global Impression-Improvement (CGI-I) Score at Week 12

Key Secondary Endpoint

Change from Baseline to Week 12 in:

  • Communication and Symbolic Behavior Scales Developmental Profile™ Infant-Toddler Checklist- Social Composite Score (CSBS-DP-IT Social)
03

Conditions studied

  • Rett Syndrome

Keywords

  • Rett syndrome,
  • Genetic Diseases, X-Linked
04

Who can participate

Ages eligible
5 Years to 20 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female subjects 5 to 20 years of age, inclusive, at Screening
  2. Body weight ≥12 kg at Screening
  3. Can swallow the study medication provided as a liquid solution or can take it by gastrostomy tube
  4. Has classic/typical Rett syndrome (RTT)
  5. Has a documented disease-causing mutation in the MECP2 gene
  6. Has a stable pattern of seizures, or has had no seizures, within 8 weeks of Screening
  7. Subjects of must abstain from sexual activity for the duration of the study and for at least 30 days thereafter or must agree to use acceptable methods of . Subject must not be pregnant or breastfeeding.
  8. The subject's caregiver is English-speaking and has sufficient language skills to complete the caregiver assessments
  9. Subject and caregiver(s) must reside at a location to which study drug can be delivered and have been at their present residence for at least 3 months prior to Screening

Exclusion criteria

EXCLUSION CRITERIA

  1. Has been treated with insulin within 12 weeks of Baseline
  2. Has current cardiovascular, endocrine (such as hypo- or hyperthyroidism, Type 1 diabetes mellitus, or uncontrolled Type 2 diabetes mellitus), renal, hepatic, respiratory or gastrointestinal disease (such as celiac disease or inflammatory bowel disease) or has major surgery planned during the study
  3. Has a history of, or current, cerebrovascular disease or brain trauma
  4. Has significant, uncorrected visual or uncorrected hearing impairment
  5. Has a history of, or current,
  6. Has a known history or symptoms of long syndrome
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    Bionetide

    Experimental: Bionetide Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

    Drug: Bionetide

  • Placebo comparator
    Placebo

    Placebo: Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

    Drug: Placebo

Interventions

  • DrugBionetide

    Bionetide solution of 20-40 mL based on the subject's weight at Baseline, administered twice daily by mouth or gastrostomy tube (G-tube)

    Also known as: NA-921

  • DrugPlacebo

    Placebo • Bionetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

    Also known as: Placebo of Bionedtide, NA-921 placebo

06

What researchers measure

Primary outcomes

  1. Rett Syndrome Behavior Questionnaire (RSBQ) Total Score - Change From Baseline to Week 12

    The RSBQ is a 45-item caregiver-completed rating scale that includes 45 items, 39 of them grouped into 8 subscales, whose ratings reflect the severity and frequency of symptoms. Items are rated as 0 (not true), 1 (somewhat or sometimes true), or 2 (very true). The 8 subscales are general mood, breathing problems, hand behavior, face movements, body rocking/expressionless face, night-time behaviors, fear/anxiety, and walking/standing. Scores for item 31 are reversed in the calculation of the total score. The total score ranges from 0 to 90 and is calculated as the sum of the item scores. Higher scores mean worse behavior.

    Time frame: Baseline and Week 12

  2. Clinical Global Impression-Improvement (CGI-I) Score at Week 12

    To rate how much the subject's illness has improved or worsened relative to a baseline state, a 7-point scale is used from 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse.

    Time frame: 12 Weeks Treatment Duration

Secondary outcomes

  1. Change From Baseline to Week 12 in Communication and Symbolic Behavior Scales Developmental

    Standardized screening scale for assessing communication and pre-linguistic skills in young children 12-24 months and can be used with older children with developmental delay. The CSBS-DP includes a suite of three separate measures: The Infant-Toddler Checklist, a follow-up Caregiver Questionnaire and a Behavior Sample. In this study only the Infant-Toddler (CSBS-DP-IT) Checklist was used. The CSBS-DP-IT Checklist is a 24-item rating scale and each item is scored using a three-level rating of frequency: "not yet", "sometimes" and "often". The CSBS-DP-IT Social Composite score the range was 0 to 26 and a higher score represented a worse outcome. Three composite scores can be calculated: 1) Social Composite; 2) Speech Composite; 3) Symbolic Composite.

    Time frame: 12 Weeks Treatment Duration

  2. Change From Baseline to Week 12 in Impact of Childhood Neurologic Disability Scale (ICND) Total Score

    The Impact of Childhood Neurologic Disability (ICND) scale evaluates the effect of four conditions or health problems on 11 aspects of a child's or family's life as "A lot", "Some", "A little", "Not at all", or "Does not apply". The four conditions or health problems are 1) inattentiveness, impulsivity, or mood, 2) ability to think and remember, 3) neurologic or physical limitations, and 4) epilepsy. The ICND score the range of 0 to 132 and a higher score represents a worse outcome.

    Time frame: 12 Weeks Treatment Duration

  3. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Hand Function (RTT-HF)

    Clinical assessment of the subject's ability to use their hands for functional purposes (such as reaching for and grasping objects, self-feeding, or drawing). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

    Time frame: 12 Weeks Treatment Duration

  4. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ambulation and Gross Motor Skills (RTT-AMB)

    Clinical assessment of the subject's ability to sit, stand, and ambulate (e.g., walking, running, and climbing stairs). The assessment was made on an 8-point Likert scale (0 to 7), with 0 denoting normal functioning and 7 as the most severe impairment.

    Time frame: 12 Weeks Treatment Duration

  5. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Ability to Communicate Choices (RTT-COMC)

    Clinical assessment of the subject's ability to communicate their choices or preferences, which can include the use of nonverbal means such as eye contact or gestures. The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

    Time frame: 12 Weeks Treatment Duration

  6. Change From Baseline to Week 12 in Rett Syndrome Clinician Rating of Verbal Communication (RTT-VCOM)

    Clinical assessment of the subject's ability to communicate verbally (e.g. words and phrases). The assessment is made on an 8-point Likert scale (0-7) with 0 denoting normal functioning and 7 the most severe impairment.

    Time frame: 12 Weeks Treatment Duration

  7. Change From Baseline to Week 12 in Clinical Global Impression-Severity (CGI-S)

    A 7 point scale that rates the severity of the subject's illness at the time of assessment, relative to the clinician's experience with subjects who have the same diagnosis. A subject is assessed on severity of illness at the time of rating: 1, normal, not at all ill; 2, borderline ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

    Time frame: 12 Weeks Treatment Duration

  8. Change From Baseline to Week 12 in Rett Syndrome Caregiver Burden Inventory (RTT-CBI) Total Score (Items 1-24)

    The Rett Syndrome Caregiver Burden Inventory (RTT-CBI) scale is intended to directly address caregiver burden and indirectly assess the significance of treatment effects on function in the context of activities of daily living. Ratings are on a 5-point Likert scale including: 0-never; 1-rarely; 2-sometimes; 3-frequently and 4-nearly always. As in the original Caregiver Burden Inventory, the RTT-CBI has 24 negatively worded items (items 1 through 24) yielding a total score up to 96. The RTT-CBI the range is 0 to 96 and a higher score represents a worse outcome.

    Time frame: 12 Weeks Treatment Duration

  9. Change From Baseline to Week 12 in Overall Quality of Life Rating of the Impact of Childhood Neurologic Disability Scale (ICND)

    The overall quality of life of the subject is also rated by responding to the following: "Please rate your child's overall 'Quality of Life' on the scale below. Choose the number which you feel is best and circle it." The choices range from 1 ("Poor") to 6 ("Excellent").

    Time frame: 12 Weeks Treatment Duration

07

Study locations

18 of 18 sites recruiting
  • Biomed Testing Facility # BIO-01-85012
    Phoenix, Arizona 85012, United States
    Recruiting
  • Biomed Testing Facility # BIO-05-92093
    La Jolla, California 92093, United States
    Recruiting
  • Biomed Testing Facility # BIO-04-90095
    Los Angeles, California 90045, United States
    Recruiting
  • Biomed Testing Facility # BIO-03-95817
    Sacramento, California 95817, United States
    Recruiting
  • Biomed Testing Facility # BIO-02-94104
    San Francisco, California 94104, United States
    Recruiting
  • Biomed Testing Facility #BIO-06-80042
    Aurora, Colorado 80042, United States
    Recruiting
  • Biomed Testing Facility #BIO-07-33606
    Tampa, Florida 33606, United States
    Recruiting
  • Biomed Testing Facility #BIO-08-60612
    Chicago, Illinois 60612, United States
    Recruiting
  • Maryland Locations Biomed Testing Facility #BIO-9-21205
    Baltimore, Maryland 21205, United States
    Recruiting
  • Biomed Testing Facility #BIO-10-02115
    Boston, Massachusetts 02115, United States
    Recruiting
  • Biomed Testing Facility #BIO-13-10467
    The Bronx, New York 10467, United States
    Recruiting
  • Biomed Testing Facility #BIO-17-19104
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Biomed Testing Facility #BIO-19-77030
    Houston, Texas 77030, United States
    Recruiting
  • Biomed Testing Facility #BIO-20-98105
    Seattle, Washington 98105, United States
    Recruiting
  • Biomed Research Unit-BIO-23-NSW 2050
    Camperdown, New South Wales 2050, Australia
    Recruiting
  • Biomed Research Unit-BIO-24-NSW-4101
    South Brisbane, Queensland 4101, Australia
    Recruiting
  • Biomed Research Unit-BIO-21-VIC-3084
    Heidelberg West, Victoria 3084, Australia
    Recruiting
  • Biomed Research Unit- BIO-22-VIC 3010
    Parkville, Victoria 3010, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — We do not plan to make individual participant data (IPD) available to other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Feb 21, 2025
StartEst.
Sep 30, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06840496
Lead sponsor
Biomed Industries, Inc.
Collaborators
Bioneurals Ltd
Responsible party
Sponsor
First posted
Feb 21, 2025
Start date
Sep 30, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

David L Nguyen, PhD
Contact
research@biomedind.com
1-800-824-5135
Jennifer Thomposn, MS
Contact
research@biomedind.com
1-800-824-5135
Lloyd L Tran, PhD
study director · Biomed Industries, Inc.
David Nguyen, PhD
study director · Biomed Industries, Inc.
Zung V Tran, PhD
study director · Biomed Industries, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion